Drigotas Claire, Loftus Alexander W, Ammori John B, Rothermel Luke D, Hoehn Richard S
Division of Surgical Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
J Surg Oncol. 2025 Feb;131(2):310-315. doi: 10.1002/jso.27882. Epub 2024 Sep 10.
Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to chemotherapeutic agent, dose, administration temperature, or duration and limited literature comparing outcomes in different regimens. In this study, we analyze common practices and outcomes of published HIPEC regimens to gain insight into current practice to inform future directions of study. We conducted a literature search for investigational studies of CRS and HIPEC for MPM treatment in adults and identified 35 such articles. These studies were analyzed for institution type and location, drug regimens, perfusion temperatures and time, and study outcomes including median survival, complication rates, and perioperative mortality rates. On review, there is significant heterogeneity in HIPEC regimens and outcome reporting metrics, suggesting a need for multi-institutional standardized study protocols to better determine the safest and most efficacious treatment regimen.
减瘤手术（CRS）联合术中温热腹腔内化疗（HIPEC）已被证明可提高恶性腹膜间皮瘤（MPM）患者的生存率。目前，关于化疗药物、剂量、给药温度或持续时间，尚无标准化的HIPEC方案，且比较不同方案疗效的文献有限。在本研究中，我们分析已发表的HIPEC方案的常见做法和结果，以深入了解当前的实践情况，为未来的研究方向提供参考。我们对关于CRS和HIPEC治疗成人MPM的研究进行了文献检索，共识别出35篇此类文章。对这些研究进行了机构类型和地点、药物方案、灌注温度和时间以及研究结果（包括中位生存期、并发症发生率和围手术期死亡率）的分析。经审查，HIPEC方案和结果报告指标存在显著异质性，这表明需要多机构标准化研究方案，以更好地确定最安全、最有效的治疗方案。
